+86-28-82633987
Synonym name:
Catalogue No.: BP0769
Cas No.: 41743-73-1
Formula: C20H18O8
Mol Weight: 386.356
Botanical Source: Iris florentina, Iris germanica and Iris tingitana
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.
For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.
HPLC of Irisflorentin
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
85.5900
2.2666
2.2666
.0029
2.3825
67.4191
High
83.3937
2.6113
Yes
No
Yes
No
Yes
Yes
2.1
No
Yes
No
Yes
Irisflorentin (CAS No.: 41743-73-1) is a natural isoflavone compound, mainly found in the traditional Chinese medicinal material Belamcanda chinensis. As an important active ingredient in Belamander, Shino iris xanthin has attracted widespread attention due to its diverse biological activity. In recent years, with the deepening development of natural product pharmacology, Shino iris flavonin has demonstrated unique pharmacological potential in anti-inflammatory and antitumor fields, especially showing significant effects in the treatment research of malignant tumors like breast cancer. This paper will systematically review the chemical structure and physicochemical properties of Ciye iris flavin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, and explore its clinical application prospects and future research directions, aiming to provide scientific basis and theoretical support for the development and utilization of this natural product.
Ciye iris flavonin belongs to the isoflavone class of compounds, with a molecular formula of C23H22O6 and a molecular weight of 386.3560. Its structural features are typical isoflavone backbones, containing a benzene ring, an isoflavone core, and multiple hydroxyl and methoxy substituents. These functional groups endow them with unique physicochemical properties and biological activity.
In terms of physicochemical properties, the LogP value of Cino iris flavonin is 2.2666, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and distribution in the body. The polar surface area (TPSA) is 85.59 Ų, indicating a certain polarity that helps bind to biomacromolecules. Low water solubility (0.0029 mg/mL) suggests limited solubility in the aqueous phase, posing certain challenges for formulation development. The blood-brain barrier penetration ability is relatively high, indicating it may affect central nervous system diseases. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test value was 2.1, indicating a low genotoxicity risk and meeting safety requirements.
Belamcanda is mainly found in Belamcanda chinensis, a perennial herbaceous plant widely distributed in China, Japan, and the Korean Peninsula. The rhizome of Shegan is an important traditional medicinal herb, with effects such as clearing heat and detoxifying, resolving phlegm, and relieving cough. As one of the main active ingredients in Belamandera, the content and extraction purity of Tsuyono iris directly affect the efficacy of the drug.
The extraction methods mainly include solvent extraction and chromatographic separation. Common solvents include methanol, ethanol, and their aqueous solutions, and extraction efficiency is improved using ultrasound-assisted extraction or reflux extraction techniques. The extract was concentrated, separated, silicate gel column chromatography, and purified by high-performance liquid chromatography (HPLC) to obtain high-purity Irino iris xanthin. In recent years, the application of supercritical fluid extraction and membrane separation technologies has provided new ideas for improving extraction efficiency and purity. In addition, seasonal and geographic differences in plant sources significantly affect the content of iris flavin in Subeno and require control and optimization.
The pharmacological activities of Shino iris flavonin cover multiple aspects, including anti-inflammation, anti-tumor, antioxidant, and immunomodulatory effects, with particular performance in breast cancer research.
Anti-inflammatory effects
Shino iris xanthin can significantly inhibit the transcription and translation of induced nitric oxide synthase (iNOS), reducing nitric oxide (NO) production and thereby alleviating inflammatory responses. Its anti-inflammatory mechanism is closely related to the regulation of the NF-κB signaling pathway, which can suppress pro-inflammatory factor expression and reduce tissue inflammatory damage.
Antitumor activity
In breast cancer cell models, Shino iris xanthin exhibited effects of inhibiting cell proliferation, inducing apoptosis, and suppressing tumor metastasis. Its antitumor effects involve regulation of multiple signaling pathways, including activation of the AMPK (PRKAA1) pathway, inhibition of STAT3 and BCL2 expression, regulation of estrogen receptor β (ESR2) activity, inhibition of multidrug resistance-related proteins ABCB1 and ABCG2, reduction of protein kinase Cα (PRKCA) and matrix metalloproteinase 2 (MMP2), and suppression of microtubule-associated protein Tau (MAPT) and lymphocyte-specific protein tyrosine kinase (LCK). Thus, it exerts comprehensive anti-cancer effects.
Antioxidant and immunomodulatory
Shino iris reduces oxidative stress damage by scavenging free radicals and enhancing antioxidant enzyme activity. At the same time, it has a regulatory effect on immune cell function, promotes immune system homeostasis, and aids in disease prevention and treatment.
The multi-target mechanism of iris xanthin provides the molecular basis for its pharmacological activity. Research on breast cancer has revealed its key targets and signaling pathways:
Additionally, Shino iris xanthin helps block the inflammatory process by inhibiting iNOS and NO production, reducing the inflammatory microenvironment.
Ciye iris xanthin has a good medicinal foundation. Its molecular weight is moderate (386.3560), meeting the drug affinity requirements of the Lipinski rule. The LogP value was 2.2666, indicating moderate lipophile, which is beneficial for cell membrane penetration and distribution in vivo. TPSA was 85.59 Ų, indicating moderate polarity, which is favorable for binding to target proteins.
Low water solubility (0.0029 mg/mL) is the main bottleneck in formulation development, requiring improved bioavailability through technologies such as nanocarriers, liposomes, or solid dispersions. Its high blood-brain barrier penetration potential suggests its potential for treating central nervous system diseases, but potential central toxicity risks should also be considered.
In terms of safety, the hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. Ames test results showed low genotoxicity risk and met drug safety requirements. Currently, in vivo pharmacokinetic studies are limited. Preliminary data indicate that the oral bioavailability of Ciye iris xanthin is limited, and in vivo metabolism mainly passes through hepatic enzyme systems. The metabolites and their activity still require further study.
As a multi-target, multifunctional natural isoflavone, Ciye iris has broad clinical application potential. Its antitumor activity in breast cancer treatment is particularly outstanding. In the future, it can be used as an adjunct therapy in combination with existing chemotherapy or targeted drugs to overcome resistance and improve treatment outcomes. Moreover, its anti-inflammatory and immunomodulatory effects offer new ideas for the treatment of chronic inflammatory diseases and immune-related disorders.
During clinical translation, it is important to address the low water solubility and bioavailability issues of Ciye iris flavonin, and to improve its in vivo stability and targeting through drug formulation innovation. At the same time, systematic pharmacokinetic and toxicological studies form the foundation for clinical application, requiring large-scale animal experiments and preclinical studies.
Future research should focus on:
1. The interaction mechanisms between iris flavin and key breast cancer targets are being deepened through structural biology and computational simulations;
2. Optimize extraction and purification processes to ensure raw material quality and batch consistency;
3. Develop efficient and safe drug delivery systems to improve drug delivery efficiency;
4. Assess its therapeutic potential in other tumor types and inflammatory diseases;
5. Conduct clinical trials to verify their safety and effectiveness.
As an important isoflavone active ingredient in Shegan, Shiye iris xanthin demonstrates promising drug development potential due to its multi-target regulation and significant anti-inflammatory and antitumor activity. Its unique molecular structure and physicochemical properties provide the basis for pharmacological action, and druggability evaluations indicate its potential as a clinical drug candidate. In the future, through in-depth mechanistic research, formulation optimization, and clinical validation, Ciye iris flavonin is expected to become a new natural drug for the treatment of breast cancer and related diseases, contributing significantly to the development of natural product pharmacology.
Shenshuai
Wenjing
Hedandan
